There’s a pattern I’ve learned to recognize over the years. It starts with whispers. Quiet accumulation. Money moving before the crowd notices.

Back in 2022… I started telling my readers to get into gold and precious metals.

Here’s what I saw…

Central banks around the world were buying bullion. The biggest kahuna of them all, the U.S., was piling on debt.

Those two factors alone were enough to ignite more buying ahead.

Fast-forward to 2026… I nailed it. Gold topped $4,635 an ounce (up 72% year over year), silver hit $92 an ounce (up 200% in a year) – validating those early signals.

Now I’m telling you to buy stocks in the biotech sector.

Here’s why…

Big pharma is sitting on a patent cliff that’s about to become a revenue catastrophe.

Between 2026 and 2030, the sector faces a “super-cliff” with $180 billion to $236 billion in annual revenue at risk from patent expirations.

I’m talking about blockbusters like Merck’s Keytruda ($25 billion in annual sales), expiring in 2028… Pfizer’s Ibrance ($6.4 billion), going off patent in 2027… and dozens more.

They have to replace that revenue – and fast. That urgency is driving an M&A explosion.

Biotech M&A exploded 73% to $228 billion in 2025 – and analysts predict more than 20 deals over $1 billion each in 2026.

Just look at what happened with obesity drugmaker Metsera last year.

When Pfizer and Novo Nordisk got into a bidding war over the company, Metsera’s shares doubled as the price escalated from initial bids of $4.9 billion to Pfizer’s winning $10 billion offer.

Or take Revolution Medicines (RVMD), which jumped 29% on Merck takeover rumors, pushing its market cap near $20 billion.

These aren’t small moves. This is a sector where triple-digit gains are the norm during takeovers.

In the War Room, we’ve already cleaned up twice in the past two years on State Street SPDR S&P Biotech ETF (XBI), which surged 36% in 2025 alone.

But that’s not where the big money will be made.

The big money will come from individual stocks that no one is looking at… no one but big pharma.

It’s a sector ripe with opportunities.

YOUR ACTION PLAN

Two under-$10 stocks are on my radar now… and one of them is under $5.

Both have huge potential as standalone companies or takeover targets.

A third stock is a biotech play that uses AI to develop drugs.

That’s just three out of many opportunities in this sector.

These plays are still relatively unknown to most people, but not to Big Pharma.

They’re arguably the most knowledgeable about which companies have potential and which don’t.

And they have the deep pockets to make multiple bets. With $1.2 trillion in acquisition capacity burning a hole in their balance sheets and pipelines that desperately need replenishing, they’re ready to write big checks.

The data backs up what I’m seeing. There were 129 deals worth $138 billion in biopharma alone last year, with the October-November period seeing a $36 billion surge.

The feeding frenzy is just getting started.

Don’t miss this like the crowd missed gold at $1,800. The biotech takeover wave is here.

FUN FACT FRIDAY

In 1886, Atlanta pharmacist John Pemberton created “Coca-Cola” as a brain tonic and headache remedy, mixing coca leaf extract (with about 9 mg of cocaine per glass initially) and kola nut extract (containing caffeine).

He sold it at soda fountains for ailments like morphine addiction, indigestion, and nerve issues. It was marketed as a “valuable brain tonic” before becoming the world’s most iconic soft drink.